

GOVERNMENT OF REPUBLIC OF TRINIDAD AND TOBAGO

MINISTRY OF HEALTH CHEMIST- FOOD AND DRUGS DIVISION

NEW DRUG SUBMISSION FORM

Guidelines:

In order to expedite the processing of your New Drug Submissions, please ensure/provide that: -

 (a) The New Drug Submission Forms are filled out properly. <u>As much information as possible must be filled out on the forms provided.</u>

DO NOT PUT - "SEE DOSSIER"

You may use a blank sheet of paper if more space is required and attach to the form.

- (b) All relevant technical data such as clinical studies, product description, product formulation/specification, methods of analysis, certificate of analysis must be provided to support each new Drug Submission. (See summary of requirements attached).
- 2. Each drug is properly certified <u>original</u> "Free Sale Certificate"/"Certificate of Pharmaceutical Product" (CPP) is required from the relevant Health Authorities.
- 3. Five (5) samples of each drug be provided in its finished pharmaceutical form in which it is to be sold.
- 4. Sample(s) of the active ingredient(s) be provided.
- 5. **REGISTRATION FEE:** \$750.00 (T.T.) payable in advance.

(Items1 (a) & (b) must be in duplicate).

(Photocopies of this form are acceptable)

Checklist To be completed by Applicant



TRINIDAD AND TOBAGO MINISTRY OF HEALTH CHEMISTRY/FOOD AND DRUGS DIVISION

SUMMARY OF REQUIREMENTS FOR NEW DRUG SUBMISSION

)	Certificate	ın respec	t of Imported Drugs	Manufacture/Importer/Agent
	□ F C) - - O 4:6:	anta Original	Name & Address
	☐ Free S	ale Certifi	cate - Original	
		or		
	☐ Certific	ate of Pha	rmaceutical Product - Original	
	(2)	Chemic	al Documentation	Name of Drug/Form/Strength
		(A)	Finished Product	
			 □ Specifications □ Method of Analysis □ Certificate of Analysis - Original □ Stability Data □ Disintegration □ Dissolution Profile □ Five (5) Samples 	
		<u>(B)</u>	Active Ingredient(s)	
			 □ Specifications □ Method of Analysis □ Certificate of Analysis (each ingredie □ One (1) gram of each 	nt) - Original
	(3)	<u>Pharma</u>	ceutical Documentation	
		(A)	Pharmacodynamic data	
			☐ General Pharmacology☐ Tests supporting efficacy	
		(B)	Pharmacokinetic data	
			 □ Absorption □ Distribution □ Biotransformation/Metabolism □ Excretion □ Biological equivalence 	

	(C)	Pharmacotherapeutic data
		☐ Therapeutic uses☐ Clinical trials☐ Therapeutic equivalence
	(D)	Toxicity data
		☐ All types
		N.B. Data: - Published and In-house.
(4)	Manı	ufacturing Details
		Manufacturing/Unit Composition Formula Brief Manufacturing Direction/Procedure Brief Manufacturing Controls Sampling and Testing Procedures GMP Certificate
(5)	Pack	aging Materials (Containers and Closures)
		Description Composition Size and dimension requirements (guage, thickness, etc.) with target value and acceptable tolerances Colour
		Processes necessary to make the article acceptable to pharmaceutical production (e.g. coating, washing, sterility of surfaces, etc.) Samples
(6)	Ink a	and Printing
		Colour of Ink Chemical Composition of Ink Description of Ink (colourfast, light resistant, rub resistant, reflectance, etc.) Other characteristics of Ink (odour, distribution, etc.) Printing - capacity to smear, smudge, scoff or be removed during normal handling of the package
(7)	Pack	age Insert
		Where applicable (Prescription Drugs) Standard Requirements

ALTERNATIVE/HERBAL MEDICINES IN TRINIDAD AND TOBAGO

The history of man has shown that multiple choices exist for protecting human health. Today's worldwide revival in the interest of natural products as preventative and therapeutic agents and the accompanying high demand for natural remedies have drawn the attention of the Ministry of Health in Trinidad and Tobago.

The Ministry has a responsibility to protect the health of the citizens. This requires the establishment of rules to govern the registration, importation, manufacture, storage, distribution, sale and use of herbal medicinal products. This is a special responsibility of the Chemistry/Food and Drugs Division in Port of Spain.

A Herbal Sub-Committee has been established by the Drug Advisory Committee to advise and assist the latter Committee on standards, schedules and conditions of sale for herbal medicinal preparations, and any other matters connected therewith.

The Drug Advisory Committee recommends to the Honourable Minister of Health, products for Approval.

The Herbal Sub-Committee consists of persons with interests and expertise in taxonomy, pharmacy, pharmacognosy, pharmacology, chemistry, conventional medicine and herbal medicine.

Assessment for product registration

Any drug, if unknown by name, form, properties and actions would cause complications. So too, would A known drug if badly administered. To ensure that safe and efficacious herbal drugs reach the consumer, the following are considered by the Sub-Committee in the assessment of each herb and herbal medicinal product:

- 1. Nomemclature
- 2. Part of plant used
- 3. Historical Aspects
- 4. Habitat
- 5. Botanical Description
- 6. Pharmcognosy
- 7. Phytochemistry

- 8. Properties
- 9. Pharmacology
- 10. Clinical Aspects
- 11. Safety
- 12. Indication
- 13. Formulation
- 14. Dosage

During the last five (5) years approximately 13% of the approved medicines were of herbal origin.

Requirements for the label of a Herbal Medicine:

The label of a package of a Herbal Medicine shall carry -

- (a) on the main panel of both the inner and the outer labels -
 - (i) the name (Proper or Common), dosage form and the standard, if any, under which the herbal medicine was manufactured:
 - (ii) a correct statement of the net contents in terms of weight, measure or number;
- (b) on both the inner and outer labels -
 - (i) the name of the manufacturer or distributor of the herbal medicine;
 - (ii) the address of the manufacturer or distributor, except that where the immediate container contains five milliliters or less, this statement need not be made on the inner label;
 - (iii) in the case of a herbal medicine which consists of more than one ingredient, a quantitative list of the active ingredients;
 - The Botanical Name of the plant(s) used and part(s) thereof, shall be declared.
 - the common or vernacular name of plant(s) used may be declared.
 - (iv) dosage regimen and adequate directions for use in the English Language;
 - (v) the expiry date;
 - (vi) directions as to the type of storage necessary to maintain the potency, efficacy, safety or properties of the herbal medicine:
 - (vii) a declaration of any warnings or contraindications, if applicable;
 - (viii) the declaration;

CAUTION: "Keep out of the reach of children".

"If pregnant or breast feeding ask a health care professional before use".

- (c) on any panel, including the panel at the bottom of the package -
 - (i) the batch or lot number; and
 - (ii) any registration number, if applicable.

For Official Use

Receiving No: Control No: DAN No:

To be filled out by Applicant upon presentation of New Drug Submission/Supplemental Submission

(1)	Name of Drug/Form/Strength :			
(2)	Name and Address of Manufacturer or :.			
	<u>Distributor:</u>			
(3)	Phone Number (if local manufacturer):			
(4)	Country of Origin:			
(5)	Name & Address of Importer:			
(6)	Phone Number:			
(7)	List of ingredients (Active Only)			
	NAME	QUANTITY	NAME	QUANTITY
(8)	Claims/Indications:			
• • • •				
• • • •				
••••				

TRINIDAD AND TOBAGO

NEW DRUG SUBMISSION FORM

Second Schedule, Division 3, Food and Drugs Act Chap 30:01

To: The Chief Chemist/Director of Food and Drugs, #115 Frederick Street, Port of Spain, Trinidad.

	New Drug Submissio information IN DUPLICA				
 (b) a statement of all is contra-indication as in which it is to be (c) details of tests app (d) labels and samples (e) samples of the contraction (f) certificates as specificates 	e New Drug, its proper raingredients, route of admend side-effects (if known e sold; blied to control potency, is of the new drug in the imponents - active ingrediction (g) to (j) in paramond and Drugs Regulation	ninistration on the purity and finished principle in the	on, dosage, construction of the safety of meaning the safety of meaning the safety of	claims to be made, f pharmaceutical for new drugs; cal form; (Note 1)	[] rm [] [] [] []
Canada F.D.A., U.S.A.	[]			nited Kingdom ustralia	[]
	te or City authorities in the	United S	tates respection	ng the sale	
and conditions	of sale in the United States	;			[]
• /	lish Language recognise sing the safety of new dr		_ 1	*	
Belgium France	[] Nether	erlands en	[]	Denmark	[]
(i) certificates (with E	English translation) from	other au	thorities in		
(j) detailed reports of new drug (Note 2).	animal test [] and/or	clinical t	(2); rials [] to	establish the safety	of the
dosage, or strength, pu	m you of any change ma arity, quality of the drug 5 of this Division of the	which m	akes them si		
	nform you of any report th the use of this New D				
Date		I	mporters/Ma	nufacturers Agent	

in Trinidad and Tobago

NEW DRUG SUBMISSION FORM (TYPE OR FILL IN BLOCK LETTERS)

NGREDIENTS:		
SEE NOTES)	HANTITY OD 0/	OLIANTITY OD 0/
Q	UANTITY OR %	QUANTITY OR %
1	7	
2	8	
}	9	
	10	
5	11	
5	12	
	CLAIMS, INDICAT	TONS
KNO	WN CONTRA INDICATION	NS SIDE-EFFECTS
KNO	WN CONTRA INDICATION	NS SIDE-EFFECTS
KNO	WN CONTRA INDICATION	NS SIDE-EFFECTS
	WN CONTRA INDICATION	NS SIDE-EFFECTS
	WN CONTRA INDICATION	NS SIDE-EFFECTS
OOSAGE		NS SIDE-EFFECTS
OOSAGE MANUFACTURER	NAME:	NS SIDE-EFFECTS
OSAGE MANUFACTURER Complete Name &		NS SIDE-EFFECTS
OSAGE MANUFACTURER Complete Name &	NAME:	NS SIDE-EFFECTS
MANUFACTURER (Complete Name & Address)	NAME: ADDRESS:	NS SIDE-EFFECTS
MANUFACTURER (Complete Name & Address)	NAME: ADDRESS: NAME:	NS SIDE-EFFECTS
MANUFACTURER (Complete Name & Address) IMPORTER/AGENT (Complete Name & Address)	NAME: ADDRESS:	NS SIDE-EFFECTS

Active ingredients must be listed before inactive ingredients. Quantities should be given in appropriate units, or in percentages (for creams, liquids), or in amounts per ml or per ampoule.

FOR OFFICIAL USE ONLY

CONDITION OF SALE:

- 1. FREE SALE
- 2. THIRD SCHEDULE
- 3. CONTROLLED
- 4. DEFERRED

COMMENTS: